An observational study in Sickle Cell Disease, sponsored by Hanane EL KENZ. Withdrawn at 2 sites in Belgium. Per ClinicalTrials.gov, last updated 2018-07-26.
Sponsored by Hanane EL KENZ · Observational
Sickle cell patients have a high prevalence of alloimmunization. This high rate of alloimmunization can be partially explained by the existence of an antigenic difference between the predominantly Caucasian donor population and the sickle cell patients of African origin. Genetic and environmental risk factors have also been described.
The main risk factors that have been shown in retrospective or cross-sectional studies are some HLA alleles, the age of the patient, the number of leukocyte-depleted erythrocyte concentrates (CED) transfused, the number of transfusion episodes, the age of the CEDs, the existence of an inflammatory event at the time of transfusion and the presence of anti-erythrocyte autoantibodies.There is also evidence of an impaired TH response but the underlying immunological mechanism is not fully understood.
The aim of this study is to study the prevalence and the risk factors for anti-erythrocyte alloimmunization in pediatric and adult patients with Sickle Cell Disease (with a SS genotype) who are being followed at Queen Fabiola University Children's Hospital (HUDERF) and at the CHU Brugmann Hospital. The identification of risk factors would allow the investigators to improve, or at least adapt, their transfusion policy to certain clinical or immuno-haematological situations.
Sickle cell disease patients (HbSS genotype) with a history of blood transfusion within the CHU Brugmann and the Queen Fabiola University Hospitals.
Exclusion Criteria:
Sickle cell disease patients with a SS genotype having an history of blood transfusions within the CHU Brugmann and the Queen Fabiola Children's Hospitals.
Other: Medical file data collection
The information described in the 'outcome measures' section will be collected from the medical files of the patients.
Date of birth
Date of birth
Time frame: january 2013-december 2017
Sex
Sex
Time frame: january 2013-december 2017
Blood group
Blood group
Time frame: january 2013-december 2017
Extended phenotype
Sickle cell disease extended phenotype
Time frame: january 2013-december 2017
Antibodies
Presence/absence of irregular anti-erythrocytes antibodies (RAI)
Time frame: january 2013-december 2017
Number of blood transfusions
Number of blood transfusions
Time frame: january 2013-december 2017
Number of blood transfusions
Number of blood transfusions
Time frame: From birth till the first positive RAI test (up to 50 years)
Auto antibodies
Presence/absence of auto anti-erythrocytes antibodies (RAI)
Time frame: january 2013-december 2017
Pathology
Medical issue causing the patient to be included in a chronic blood transfusion program
Time frame: january 2013-december 2017
Duration of the chronic transfusion program
Duration of the chronic transfusion program
Time frame: january 2013-december 2017
Plan to share: No
No publications or documents are linked to this record.
This study is withdrawn, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hanane EL KENZ